Kidney Dysfunction Prediction by Serum Adropin in Type 2 Diabetes Iraqi Patients

Abstract Background: Diabetic nephropathy (DN) is a problem that arises from microvascular complications with type 2 diabetes mellitus (T2DM). It especially denotes the deterioration of renal function. Adropin, a regulatory peptide hormone, has attracted interest for its potential role in regulating metabolism, specifically glucose metabolism and insulin resistance. Objective: To assess Adropin’s role in the identification and severity of T2DM nephropathy. Methods: A cross-sectional study which involved an 88 patients with DN was conducted in the National Diabetes Center/Mustansiriyah University during the period from October 2023 to April 2024. Body mass index, blood analysis for sugar levels, lipid profile, renal function test, and albumin to creatinine ratio in urine were conducted. In addition, the content of human adropin was evaluated using an enzyme-linked immunosorbent assay. Results: Much more fasting blood sugar, glycated hemoglobin, insulin, homeostasis model assessment insulin resistance, cholesterol, triglycerides, low-density lipoprotein (LDL) and very LDL, urea, and creatinine were found in the microalbuminuria and macroalbuminuria groups of DN patients than in the normoalbuminuria group. The amount of adropin in the blood was lowered in people with microalbuminuria and macroalbuminuria (245.91 ± 59.47 and 179.86 ± 51.96 pg/ml, respectively) than in people with normoalbuminuria (377.97 ± 98.69 pg/ml) as well. While the subject attempts to identify the difference between the groups of DN, adropin works very well and is very sensitive. Conclusion: This study establishes a correlation between reduced adropin levels and impaired kidney function in individuals diagnosed with T2DM. Adropin content in the serum is able to serve as a biomarker for the early recognition of DN, by its role in glucose metabolism and insulin resistance.